Distribution of Survivorship Care Plans Lacking Among Patients with Cancer

Despite recommendations to do so, distribution of survivorship care plans still has not increased for survivors of cancer, according to a recent study.
BY KATIE KOSKO @Katie_Kosko
PUBLISHED: JANUARY 30, 2017
There was no significant increase of survivorship care plans (SCPs) given to patients with cancer from 2015 onward, despite calls from the Institute of Medicine (IOM) and the Commission on Cancer (CoC) to deliver one following completion of treatment, according to a new study.

The findings were presented during a poster session at the 2017 Cancer Survivorship Symposium held January 27-28 in San Diego.

A survey was distributed to 312 patients – 66 percent of whom had breast cancer – through social media platforms. These included Tweet chats, Facebook groups, blogs and targeted emails. The survey was conducted between March and April 2016. The researchers chose to reach cancer-related communities using social media since that is where many patients turn to in order to obtain information and communicate with others for support.

Sixty-three percent (194 patients) had completed treatment, excluding endocrine therapy. Based on this group, researchers found 88.2 percent (171 patients) did not receive an SCP, while 11.8 percent (23 patients) did receive one.

The authors on the study noted that a 2005 IOM report resulted in a call to develop survivorship programs for patients that included guidelines for monitoring and maintaining their health. In January 2015, the CoC set a standard requiring the delivery of an SCP to patients at the completion of treatment. However, a survey given at that time, found just over a third of hospital programs felt confident that the requirement could be met.

The findings of this study appear to show this is where institutions are still struggling years later.

A survivorship care plan should be created by a patient’s physician to guide them in their journey after cancer. The American Society of Clinical Oncology (ASCO) offers its own plan that “contains important information about the given treatment, the need for future check-ups and cancer tests, the potential long-term late effects of the treatment you received and ideas for improving your health.”

Interestingly, the survey also identified that a majority (65 percent) of patients who did not get an SCP felt that one would have been helpful following completion of their treatment. Of the SCPs that were received, most were provided to patients in paper form. Survey results found that 50 percent of patients would prefer an SCP to be delivered on paper, 41 percent would prefer it through an online patient portal and 9 percent would prefer email.

Overall, the authors suggested that the CoC may not reach its goals for SCPs based on these findings.

Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
x-button
Special Feature
Share Your Art
Related Articles
The Logistics of Multigene Panel Testing in Breast Cancer
Generally, health insurance covers the cost of genetic testing recommended by a physician. However, some patients who had BRCA testing in the past have had trouble getting reimbursed for a follow-up panel test. The outof- pocket cost for a single panel test can be up to $5,000, although lower-cost tests are available.
Young Patients With Cancer Don't Always Get the Info They Need
When treated for cancer, young patients don’t always get the information they need from doctors.
Immunotherapy Offers New Optimism for Patients With Merkel Cell Carcinoma
Although chemotherapy has been used to treat patients with Merkel cell carcinoma, immunotherapy agents show great promise, according findings presented at the 2017 World Congress of Melanoma.
Related Videos
Preserving Eyebrows During Chemotherapy Treatment
Renata Marie Vestevich, founder and developer of Essential Eyebrow Solution (EES), discusses how this topical solution may be able to help patients keep their eyebrow hair while undergoing chemotherapy.
Does Age Affect Cancer Genomics?
Garrett Frampton, associate director of Cancer Genomics at Foundation Medicine, discusses recent research about genetic mutations that are more common in certain age groups.  
Facing Advanced Cancer's Struggles With CALM
Gary Rodin, M.D., head of the Department of Supportive Care at Princess Margaret Cancer Centre, in Toronto, Canada, discusses CALM, an intervention designed to help patients with advanced-stage cancer cope and talk about their concerns.
x
//For side ad protocol